We've sched­uled your Type T meet­ing with FDA com­mish Scott Got­tlieb, where you can learn the art of rapid fire R&D

Here we’re in­tro­duc­ing the Type T(wit­ter) meet­ing with the head of the FDA on stream­lined drug de­vel­op­ment.

Any­body who’s been pay­ing at­ten­tion to our sur­veys of the End­points 100 would not be sur­prised to learn that a large ma­jor­i­ty of biotech ex­ecs have a big crush on FDA com­mis­sion­er Scott Got­tlieb. One big rea­son for the love af­fair be­tween the in­dus­try and the com­mish is that from the ex­ecs’ per­spec­tive Got­tlieb’s push­ing to make the agency far more re­spon­sive to crit­i­cism and the need to bat­ter down some long­stand­ing hur­dles in the way of drug de­vel­op­ers. And they want it done with­out toss­ing the gold stan­dard of R&D out the win­dow and mak­ing it a free-for-all.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.